Trial halted early in search for better liver cancer treatment
NCT ID NCT04050462
Summary
This study tested whether adding one of two experimental drugs to a standard immunotherapy (nivolumab) could shrink tumors better than the standard drug alone in people with advanced liver cancer. It was a Phase 2 trial that enrolled a small number of patients before being terminated. The main goal was to see if the combinations led to a higher rate of tumor shrinkage or disappearance.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NYU Langone Health
New York, New York, 10016, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.